European Review for Medical and Pharmacological Sciences 2010; 14: 19-23 Effects of reduced glutathione on level, total and oxidant capacity and deaminase activity

O. ATAKISI1*, H.M. ERDOGAN2, E. ATAKISI1, M. CITIL2, A. KANICI3, O. MERHAN1, M. UZUN4

1Department of Biochemistry; 2Department of Internal Medicine, College of Veterinary Medicine, University of Kafkas, Kars (Turkey); 3Department of Pharmacology and Toxicology, College of Veterinary Medicine, University of Ankara, Ankara (Turkey); 4Canakkale Onsekiz Mart University, School of Health Science, Canakkale (Turkey)

Abstract. – The aim of this study was to the formation of γ-glutamylcysteine from l-gluta- determine the effect of exogenous GSH, an im- mate and l-. In the second step, catalyzed portant antioxidant containing group, on to- by GSH synthetase (EC 6.3.2.3, GS), is tal antioxidant capacity (TAC) and total oxidant γ capacity (TOC), adenosine deaminase (ADA), a added to the C-terminal of -glutamylcysteine to significant indicator of cellular immunity, and ni- form GSH1,2. The key function of GSH molecule is tric oxide (NO) concentrations in rabbits. the maintenance of protein structure and function, Sixteen healthy New Zealand rabbits were di- the regulation of protein synthesis and degradation, vided into 2 groups as control and GSH-treated the maintenance of immune function, protection group. in control group received single against oxidative damage, and detoxification of re- intraperitoneal (ip) administration of 0.9% saline. 3,4 Rabbits in GSH-treated group received reduced active chemicals . GSH molecule also plays role 3 L-glutathione (10 mg/kg) (ip). Blood samples were in immune function . taken from the marginal ear vein 0, 3, 6 and 12 Adenosine deaminase (ADA) is an essential hours after injection. Plasma TAC and NO levels of purine . ADA catalyzes were not statistically different between control and the irreversible hydrolytic deamination of adeno- GSH group at 0 and 12 hours. Plasma TAC level sine and 2-deoxyadenosine to inosine and 2-de- was found to be significantly higher (p<0.05) while 5,6 NO level was found to be significantly lower oxyinosine, respectively . ADA is necessary for (p<0.05) in GSH treated group when compared to lymphocyte proliferation and differentiation. control group at 3 and 6 hours. Plasma TOC and Therefore, it is considered as an important immu- ADA activity were not statistically different be- noenzyme marker of mediated immunity7,8. tween control and GSH group during experiment. Nitric oxide (NO) is an endogenous reactive In conclusion, exogenous GSH resulted in an free , produced from the L-argi- alteration of TAC and NO but not TOC and ADA, nine by the enzymatic action of nitric oxide syn- so exogenous GSH may be a valuable enhancer 9 of the antioxidant system. thase (NOS) . Although various NOS isoforms have been described, only three forms, inducible Key Words: NOS (iNOS), endothelial NOS (eNOS) and neu- Total antioxidant capacity, Total oxidant capacity, ronal NOS (nNOS), have been described in de- 10,11 Nitric oxide, Adenosine deaminase, Reduced glu- tail . NO is stabilized by carrier molecule like tathione, Rabbit. reduced thiol species that preserves its biological activity. Low molecular weight such as cys- teine, GSH, and penicillamine are prime candi- dates for such carrier molecules, and they can form S-nitrosothiols on reaction with oxides of ni- Introduction trogen12. This molecule readily reacts in the pres- ence of NO to yield biologically active S-ni- Reduced glutathione (GSH) is synthesized by trosothiols that is more stable and potent than NO two sequential (ATP)-de- itself. S-nitrosothiols are unstable in aqueous solu- pendent reactions. In the first reaction, γ-glutamyl- tion. For example, S-nitrosoglutathione (GS-NO) cysteine synthetase (EC 6.3.2.2, γ-GCS) catalyzes undergoes decomposition over hours, whereas S-

Corresponding Author: Onur Atakisi, PhD; e-mail: [email protected] 19 O. Atakisi, H.M. Erdogan, E. Atakisi, M. Citil, A. Kanici, O. Merhan, M. Uzun nitrosocysteine has a half-life of less than 2 ments, Winooski, VT, USA) using commercial min13,14. GS-NO is a bioactive intermediary that kit (Rel Asssay, Gaziantep, Turkey) in plasma may regulate cellular functions and inhibits the samples. in the sample reduce dark sarcoplasmic reticulum bound kinase3. blue-green colored 2,2′-azinobis (3-ethylben- Generally S-nitrosoglutathione (GS-NO) has been zothiazoline-6-sulfonic acid) diammonium salt found endogenously in neutrophils and human air- (ABTS) radical to colorless reduced ABTS form. ways at µM concentrations15. S-nitrosothiols may The change of absorbance at 660 nm is related play the same role in the mechanism of action of with total antioxidant level of the sample 19. Endothelium-Derived Relaxing Factor (EDRF) as NO3. Some Authors have assumed that the biolog- Determination of Total Oxidant Capacity ical effects of these compounds are due to the Plasma total oxidant capacities were deter- spontaneous release of NO. However, this hypoth- mined via spectrophotometer (PowerWave XS, esis is not fully supported yet16-18. BioTek, Instruments, Winooski, VT, USA) with This study therefore aimed at determining the commercial kit (Rel Asssay, Gaziantep, Turkey). effect of exogenous GSH, an important antioxi- Oxidants present in the sample oxidize the fer- dant containing thiol group, on total antioxidant rous ion-chelator complex to ferric ion. The oxi- capacity, total oxidant capacity, and adenosine dation reaction is prolonged by enhancer mole- deaminase a significant indicator of cellular im- cules, which are present in reaction medium. The munity and NO concentrations in rabbits. ferric ion makes a colored complex with choro- mogen in an acidic medium. The color intensity is related to the total oxidant molecules present in the sample at 530 nm. Trolox and Materials and Methods standards were used for total antioxi- dant and total oxidant capacities19. Sixteen New Zealand rabbits (Laboratory Ani- mal Unit of the University of Kafkas, Kars, Turkey) Determination of Nitric Oxide Levels of both sexes, aged between 7 and 9 months were in Plasma used. The mean body weight was 2.39 ± 0.42 kg. Nitric oxide concentrations were determined They were kept in cages at room temperature (22- using a spectrophotometer (PowerWave XS, 25ºC) with a 12:12h light:dark cycle and fed a spe- BioTek, Instruments, Winooski, VT, USA) in cial pelleted rabbit diet (Bayramoglu Yem AS, plasma samples. Plasma samples were depro- Erzurum, Turkey) ad libitum. Animals were divided teinized with 10% sulphate. Total NO (ni- into 2 groups as control and GSH-treated group. trate and ) concentrations were determined Each group consisted of 8 animals and treated as colorimetrically by the acidic Griess reaction20. follows: animals in control group received a single intraperitoneal (ip) administration of 0.9% saline Determination of ADA. (Baxter, Mediflex, Eczacibasi, Istanbul, Turkey). Adenosine deaminase activity (ADA) in plasma Rabbits in GSH group were treated with a single ip was determined at 37°C according to the method administration of L-glutathione reduced (Sigma- of Giusti and Galanti21 based on the Bertholet re- Aldrich Chemie GmbH, Taufkirchen, Germany) action, formation of coloured indophenol complex dissolved in 0.9% saline at a dose of 10 mg/kg body from ammonia liberated from adenosine, and weight. Blood samples were taken from the margin- quantified colorimetrically with spectrophotome- al ear vein at 0, 3, 6 and 12 hours after injection into ter (UV-1201, Shimadzu, Japan). One unit of treated tubes. Plasma was collected by cen- ADA is defined as the amount of enzyme required trifugation at 3000 rpm for 10 min and stored at - to release 1 mmol of ammonia/min from adeno- 50°C until analyses. sine at standard assay condition. Results were ex- pressed as international unit of enzyme activity.

Biochemical Analysis Statistical Analysis The data for biochemical parameters were ana- Determination of Total lyzed by ANOVA followed by post hoc Tukey test Antioxidant Capacity using SPSS Windows 10.0. All data were present- Total antioxidant capacities were determined ed as mean ± SE. Values were considered statisti- colorimetrically (PowerWave XS, BioTek, Instru- cally significant if P value was less than 0.05.

20 Effects of reduced glutathione on antioxidative status

Results GSH, a thiol antioxidant, is known to act as pro- tector in various cytotoxic conditions22-24. In ad- Plasma TAC, TOC, NO levels and ADA activ- dition, GSH is found within the cell at millimolar ity at 0, 3, 6 and 12 hours following the treat- concentrations that serves several essential func- ments are presented in Table I. Plasma TOC and tions including protein and DNA synthesis and ADA activities were not statistically different be- amino acid transport25-27. In condition of oxida- tween control and GSH group during the experi- tive stress, the GSH/GSSG ratio from 100 to 10 ment. or even 1 have been described and found to cor- Plasma TAC and NO levels were also not sta- relate with the amount of protein mixed tistically different between control and GSH formation. The ratio of the reduced pool to glu- group at 0 and 12 hours. Plasma TAC level was tathione disulfide (GSSG) is critical to cellular found to be significantly higher at 3 (1.16±0.08 balance28. vs 0.64±0.10; p <0.05) and 6 hours (0.93±0.07 vs Studies have reported reduced GSH pool during 0.71±0.08 μmol Trolox Equiv./L; p <0.05) while cytotoxicity and oxidative stress situations22-27. In NO level was found to be significantly lower in a research involving isolated rat liver exogenous GSH treated group when compared to control GSH was shown to protect liver damage induced group at 3 (13.72±1.26 vs 18.61±0.85; p <0.05) cyanide or hypoxia and reoxygenation. Further- and 6 hours (12.28±0.68 vs 19.29±1.38 μmol; p more, several Authors have shown that addition <0.05). of exogenous GSH into perfusion medium result- ed in an increase in intracellular level in both damaged and healthy liver by entering either di- rectly or indirectly into liver cells29. When GSH, Discussion an endogen antioxidant, was given exogenously, intracellular GSH level might determined an in- Our data showed that rabbits who have re- crease in TAC level. In the present study, we as- ceived reduced glutathione had higher TAC at 3 sayed oxidative status of the reduced glutathione and 6 h of injection as compared to controls. given rabbits by using TOC and TAC as indicator

Table I. Plasma total antioxidant capacity (TAC), total oxidant capacity (TOC), nitric oxide (NO) and adenosine deaminase (ADA) activity of healthy rabbits in the treatment and control group (n=8).

Groups

Parameters Time Control Reduced glutathione

TAC (mmol Trolox Equiv./L) 0 0.60 ± 0.10a 0.60 ± 0.05a 3 0.64 ± 0.10a 1.16 ± 0.08b 6 0.71 ± 0.08a 0.93 ± 0.07b 12 0.73 ± 0.09a 0.83 ± 0.09a

a a TOC (µmolH2O2 Equiv./L) 0 0.58 ± 0.04 0.62 ± 0.09 3 0.72 ± 0.05a 0.57 ± 0.05a 6 0.57 ± 0.05a 0.62 ± 0.06a 12 0.56 ± 0.09a 0.41 ± 0.06a

NO (µmol/L) 0 19.48 ± 1.13a 20.41 ± 1.18a 3 18.61 ± 0.85a 13.72 ± 1.26b 6 19.29 ± 1.38a 12.28 ± 0.68b 12 20.50 ± 0.91a 19.16 ± 1.50a

ADA (U/L) 0 6.68 ± 0.81a 6.16 ± 0.87a 3 5.44 ± 0.44a 5.38 ± 0.40a 6 5.45 ± 0.60a 5.18 ± 0.31a 12 6.20 ± 0.60a 5.45 ± 0.30a

Values with different superscripts in the same row are significantly different at p<0.05.

21 O. Atakisi, H.M. Erdogan, E. Atakisi, M. Citil, A. Kanici, O. Merhan, M. Uzun of , reflecting the redox balance tion. Therefore, exogenous GSH may not affect between oxidation and antioxidation. It is well immune system of healthy rabbits. known that oxidative stress can be defined as an In conclusion, exogenous GSH resulted in al- increase in oxidants and/or a decrease in antioxi- teration of plasma TAC but not plasma TOC and dant capacity, and various oxidants and antioxi- plasma ADA, and reduced plasma NO may be dants have additive effects on oxidative status. due to reaction between NO and GSH. Although the concentration of plasma level of oxidants and antioxidants can be measured indi- vidually, it may not accurately reflect the oxida- tive status30. Exogenous GSH increased TAC but did not alter TOC level in this study. This may be References attributed to rabbits used that were healthy and there was no condition that incurred enough 1) MURATA K, TANI K, KATO J, CHIBATA I. Glutathione stress to cause alteration in oxidant/antioxidant production coupled with an ATP regeneration sys- tem. Eur J Appl Microbiol Biotechnol 1980; 10: system. Therefore, the plasma TOC levels did 11-21. not change. 2) MEISTER A, ANDERSON ME. Glutathione. Annu Rev Nitric oxide is a biologically active molecule Biochem 1983; 52: 711-760. with different effects on many physiological and pathological processes31. In a study by Sing et 3) WANG W, N AZZARENO B. Endogenous glutathione 13 conjugates: occurrence and biological functions. al. NO was shown to be released from nitrosog- Pharmacol Rev 1998; 3: 335-356. lutathione molecule or GSH molecule forming 4) AKKUS I. Effects of free radicals and pathophysio- compound with electrophylic molecules as NO. logical. Konya, Turkey: Mimoza; 1995. Nitrosoglutathione (GS-NO) molecule, formed by a reaction between GSH and NO, plays role in 5) EDLUND A, FREDHOLM BB, PATRIGNANI P, P ATRONO C, WENNMALM A, WENNMALM M. Release of two va- many physiologic and pathologic process sodilators, adenosine and prostacyclin, from iso- through a mechanism similar to that of NO via lated rabbit hearts during controlled hypoxia. J EDRF3,32. NO level was found decreased at 3 and Physiol 1983; 340: 487-501. 6 hours of GSH application in this study. De- 6) YASUDA J, TANABE T, H ASHIMOTO A, TOO K. Adeno- creased NO level may be related to formation of sine deaminase (ADA) activity in tissues and sera GS-NO. In fact, after administration of GSH, NO from normal and leukaemic cattle. Br Vet J 1996; was bound to GSH to form GS-NO and this re- 152: 485-488. sulted in reduced plasma NO level. Moreover, 7) KÖSE K, YAZICI C, AŞŞIOĞLU O. The evaluation of GSH injection resulted in an alleviation of ad- peroxidation and adenosine deaminase ac- verse effect of NO, also a free radical32,33. This tivity in patients with Behcet’s disease. Clin Biochem 2001; 34: 125-129. latter result may also explain why GSH injection resulted in increased plasma TAC level. 8) UNGERER JP, OOSTHUIZEN HM, BISSBORT SH, VERMAAK WJ. Serum adenosine deaminase: isoenzyme ADA, an important enzyme in the purine me- and diagnostic application. Clin Chem 1992; 38: tabolism, serves in the catalytic deamination of 1322-1326. adenosine to inosine and ammonia. It is required 9) ALDERTON WK, COOPER CE, KNOWLES RG. Nitric oxide for the lymphocyte proliferation and differentia- synthase: structure, function and inhibition. tion6,21,34,35. Elevation in the ADA activity is at- Biochem J 2001; 357: 593-615. tributed to the stimulated cell mediated immune 10) FELDMAN PL, STUEHR DJ, GRIFFITH OW, FUKUTO JM. response and could also be used as a marker of Mechanisms of mammalian nitric oxide biosyn- activated neutrophil functions during the oxida- thesis. In: Weisman, BA. et al. Eds. Biochemical, tive stress21,36. ADA results decreased in severe pharmacological and clinical aspects of nitric ox- combined immunodeficiency disease character- ide. Plenum Press, New York, 1995. ized by incompetence of both humoral and cellu- 11) GRIFFITH OW. Nitric oxide synthase inhibitors: lar immunity34. GSH also plays an important role Mechanisms of action and In vivo studies. In: in immune system along with its antioxidant ef- Weisman BA, et al. Eds. Biochemical, Pharmaco- logical and Clinical Aspects of Nitric Oxide. fect. Although ADA activity changes in diseases Plenum Press, New York, 1995. where immune system is activated or inhibited6,7, 37 12) SHIROTA FN, GOON DJ, DEMASTER EG, NAGASAWA HT. it does not change in healthy subjects , likewise Nitrosyl cyanide, a putative metabolic oxidation to rabbits of the present study, where ADA activ- product of the -deterrent agent cyanamide. ity did not altere after exogenous GSH applica- Biochem Pharmacol 1996; 52: 141-147.

22 Effects of reduced glutathione on antioxidative status

13) SINGH SP, WISHNOK JS, KESHIVE M, DEEN WM, TAN- 25) TEW KD. Glutathione-associated in anti- NENBAUM SR. The chemistry of the S-nitrosoglu- cancer drug resistance. Cancer Res 1994; 54: tathione/glutathione system. Proc Natl Acad Sci 4313-4320. 1996; 93: 14428-14433. 26) ANDERSON ME, MEISTER A. Glutathione monoesters. 14) AL-SA'DONI H, FERRO A. S-Nitrosothiols: a class of Anal Biochem 1989; 83: 16-20. nitric oxide-donor drugs. Clin Sci 2000; 98: 507- 27) ALLATORI Glutathione mercaptides as transport 520. B N. forms of metals. Adv Pharmacol 1994; 27: 271- 15) CLANCY RM, LEVARTOVSKY D, LESZCZYNSKA-PIZIAK J, 298. YEGUDIN J, ABRAMSON SB. Nitric oxide reacts with in- tracellular glutathione and activates the hexose 28) GILBERT HF. Thiol/disulfide exchange equilibria and monophosphate shunt in human neutrophils: evi- disulfide bond stability. Method Enzymol 1995; dence for S-nitrosoglutathione as a bioactive inter- 251: 8-28. mediary. Proc Natl Acad Sci 1994; 91: 3680-3684. 29) YOUNES M, STRUBELT O. Protection by exogenous glutathione against hypoxic and cyanide-induced 16) KOWALUK EA, FUNG HL. Spontaneous liberation of nitric oxide cannot account for in vitro vascular re- damage to isolated perfused rat livers. Toxicol laxation by S-nitrosothiols. J Pharmacol Exp Ther Lett 1990; 50: 229-236. 1990; 255: 1256-1264. 30) EREL O. Novel automated method to measure total 17) ROCKETT KA, AWBURN MM, COWDEN WB, CLARK IA. antioxidant response against free radical reac- Killing of Plasmodium falciparum in vitro by nitric tions. Clin Biochem 2004; 37: 112-119 oxide derivatives. Infect Immun 1991; 59: 3280- 31) HOFSETH LJ, HUSSAIN SP, WOGAN GN, HARRIS CC. Ni- 3283. tric oxide in cancer and chemoprevention. Free 18) GASTON B, DRAZEN JM, JANSEN A, SUGARBAKER DA, Radic Biol Med 2003; 34: 955-968. LOSCALZO J, RICHARDS W, S TAMLER JS. Relaxation of 32) ZENG H, SPENCER NY, HOGG N. Metabolism of S-ni- human bronchial smooth muscle by S-nitrosoth- trosoglutathione by endothelial cells. Am J Physiol iols in vitro. J Pharmacol Exp Ther 1994; 268: Heart Circ Physiol 2001; 281: H432-H439. 978-984. 33) ZAHNER H, SCHMIDTCHEN D, MUTASA JA. Ivermectin- 19) EERL O. A novel automated direct measurement induced killing of microfilariae in vitro by neu- method for total antioxidant capacity using a new trophils mediated by NO. Exp Parasitol 1997; 86: generation, more stable ABTS radical cation. Clin 110-117. Biochem 2004; 37: 277-285. 34) GIBLETT ER, ANDERSON JE, COHEN F, P OLLARA B, 20) MIRANDA KM, ESPEY MG, WINK DA. A rapid, simple MEUWISSEN HJ. Adenosine deaminase deficiency in spectrophotometric method for simultaneous de- two patients with severely impaired cellular immu- tection of nitrate and nitrite. Nitric Oxide 2001; 5: nity. Lancet 1972; 2: 1067-1069. 62-71. 35) ERKILIÇ K, EVEREKLIOGLU C, CEKMEN M, OZKIRIS A, 21) GIUSTI B, GALANTI B. Methods of enzymatic analy- DUYGULU F, D OGAN H. Adenosine deaminase en- sis. In: Bergmeyer HU, eds. Adenosine deami- zyme activity is increased and negatively corre- nase: Colorimetric method, Weinheim: Verlac lates with catalase, superoxide dismutase and Chemie; 1984. glutathione in patients with Behçet's 22) NAKAMURA Y, S HIMETANI A, FUJII H, AMANO O, SAKAGA- disease: original contributions/clinical and labora- MI H, TAKAHASHI K. Glutathione can efficiently pre- tory investigations. Mediators Inflamm 2003; 12: vent direct current-induced cytotoxicity. J Endod 107-116. 2008; 34: 693-697. 36) TRIPATHI K, KUMAR R, BHARTI K, KUMAR P, S HRIVASTAV R, 23) JONES DP. Radical-free biology of oxidative stress. SUNDAR S, PAI K. Adenosine deaminase activity in Am J Physiol Cell Physiol 2008; 295: 849-868. sera of patients with visceral leishmaniasis in In- dia. Clin Chim Acta 2008; 388: 135-138. 24) BANERJEE A, TRUEBLOOD MB, ZHANG X, MANDA KR, LOBO P, W HITEFIELD PD, HAGEN DE, ERCAL N. N- 37) ATAKISI E, KART A, ATAKISI O, TOPCU B. Acute tamox- acetylcysteineamide (NACA) prevents inflamma- ifen treatment increases nitric oxide level but not tion and oxidative stress in animals exposed to total antioxidant capacity and adenosine deami- diesel engine exhaust. Toxicol Lett 2009; 187: nase activity in the plasma of rabbits. Eur Rev 187-193. Med Pharmacol Sci 2009; 13: 239-243.

23